FDA Approved: ULTOMIRIS — Supplemental Application (Alexion Pharmaceuticals Inc.)

View source ↗

Summary

The FDA approved a supplemental application for Ultomiris (ravulizumab) submitted by Alexion Pharmaceuticals, resulting in changes to the labeling to reflect th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atypical Hemolytic Uremic Syndrome
• Generalized Myasthenia Gravis
• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• ULTOMIRIS (ravulizumab)

Snippet

SUPPL AP for ULTOMIRIS (RAVULIZUMAB)